Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
160 hedge funds and large institutions have $2.61B invested in Juno Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 55 increasing their positions, 33 reducing their positions, and 15 closing their positions.
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
67% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 33
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
21% more funds holding
Funds holding: 132 → 160 (+28)
20% more capital invested
Capital invested by funds: $2.17B → $2.61B (+$437M)
61% less call options, than puts
Call options by funds: $12.5M | Put options by funds: $31.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$103M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$58.7M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$13.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.8M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$19.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.9M |
| 3 |
MCM
Marsico Capital Management
Denver,
Colorado
|
-$5.45M |
| 4 |
JP Morgan Chase
New York
|
-$5M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$4.96M |
JUNO Hedge Fund Activity: Q4 2015 in Review
160 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q4 2015, worth a combined $2.61B — up 20% from $2.17B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new JUNO positions and 15 closed out — a net gain of 30 holders — while 55 added to existing stakes and 33 trimmed.
The largest buyer was First Trust Advisors, opening a new position worth an estimated $103M. The largest seller was Graticule Asia Macro Advisors, cutting an estimated $19.8M.
- 160 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q4 2015, up from 132 in Q3 2015.
- Funds reported $2.61B of Juno Therapeutics, Inc. stock for Q4 2015, up 20% quarter-over-quarter.
- 45 funds opened new Juno Therapeutics, Inc. positions in Q4 2015 and 15 closed out, a net change of +30 holders.
- The largest Juno Therapeutics, Inc. buyer in Q4 2015 was First Trust Advisors, an estimated $103M added.
- The largest Juno Therapeutics, Inc. seller in Q4 2015 was Graticule Asia Macro Advisors, an estimated $19.8M sold.
Based on aggregated 13F filings for Q4 2015.